Clinical Trial Update: Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328 [NA]

View source ↗

Summary

Clinical trial update noting completion of a study assessing interleukin-2 in combination with HAART for HIV-infected patients previously enrolled in ACTG 328.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• HAART (Highly Active Antiretroviral Therapy) (Highly Active Antiretroviral Therapy)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | NA | Status: COMPLETED